Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.42 |
| ▸ | ABL1 | P00519 | 4/20 | 0.42 |
| ▸ | RET | P07949 | 4/20 | 0.42 |
| ▸ | CDK7 | P50613 | 4/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.42 |
| ▸ | AURKA | O14965 | 4/20 | 0.42 |
| ▸ | JAK2 | O60674 | 4/20 | 0.42 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.42 |
| ▸ | FLT1 | P17948 | 3/20 | 0.42 |
| ▸ | CLK2 | P49760 | 3/20 | 0.42 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.42 |
| ▸ | GSK3A | P49840 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17731614 | 0.80 | HTT (0.37) | KDRCDK5AURKBCLK4ABL1 | |
| SCHEMBL1192302 | 0.77 | SMN1; SMN2 (0.53) | KDRCDK5AURKBCLK4DYRK1A | |
| SCHEMBL10147755 | 0.77 | DYRK1A (0.42) | KDRCDK5AURKBCLK4DYRK1A | |
| SCHEMBL14690389 | 0.77 | ALDH1A1 (0.46) | KDRCDK5AURKBCLK4DYRK1A | |
| SCHEMBL31588150 | 0.77 | SMN1; SMN2 (0.53) | KDRCDK5AURKBCLK4DYRK1A | |
| SCHEMBL23123363 | 0.77 | DYRK1A (0.42) | KDRCDK5AURKBCLK4DYRK1A | |
| SCHEMBL20552534 | 0.77 | DYRK1A (0.39) | KDRCDK5AURKBCLK4DYRK1A | |
| SCHEMBL2971825 | 0.77 | DYRK1A (0.39) | KDRCDK5AURKBCLK4DYRK1A | |
| SCHEMBL6950675 | 0.75 | DYRK1A (0.38) | KDRCDK5AURKBCLK4DYRK1A | |
| SCHEMBL9692091 | 0.75 | NPC1 (0.47) | KDRCDK5AURKBCLK4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174052-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170305929-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3215512-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073407-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-12 | — | — | WO | disclosed |
| US-8026241-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-7582761-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | BALAN CHENERA | 2009-06-04 | — | — | US | disclosed |
| EP-1695977-A2 | Spiro [isobenzofuran-1,4'piperidin]-3-ones and 3H-spiroisobenzofuran-1, 4'-piperidines | Neurogen Corporation (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060040964-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | BAKTHAVATCHALAM RAJAGOPAL | 2006-02-23 | — | — | US | disclosed |
| EP-1347982-B1 | SPIRO ISOBENZOFURAN-1,4'-PIPERIDIN]-3-ONES AND 3H-SPIROISOBENZOFURAN-1,4'-PIPERIDINES | NEUROGEN CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6943199-B2 | Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines | NEUROGEN CORPORATION (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1551811-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | Amgen Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050033048-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines | NEUROGEN CORPORATION | 2005-02-10 | — | — | US | disclosed |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004035549-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| US-20040072847-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NEUROGEN CORPORATION | 2004-04-15 | — | — | US | disclosed |
| EP-1347982-A2 | SPIRO ISOBENZOFURAN-1,4'-PIPERIDIN]-3-ONES AND 3H-SPIROISOBENZOFURAN-1,4'-PIPERIDINES | Neurogen Corporation (US) | 2003-10-01 | — | — | EP | disclosed |
| US-6566367-B2 | For therapy of eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension in humans, domesticated companion animals and livestock animals | PFIZER INC. | 2003-05-20 | — | — | US | disclosed |
| US-20030036652-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NEUROGEN CORPORATION | 2003-02-20 | — | — | US | disclosed |
| WO-2002048152-A2 | SPIRO[ISOBENZOFURAN-1,4'-PIPERIDIN]-3-ONES AND 3H-SPIROISOBENZOFURAN-1,4'-PIPERIDINES | NEUROGEN CORPORATION (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072847-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NPY5R, NPY4R, NPY1R | KDR 628/4885CDK5 2066/4885AURKB 4791/4885 |
| US-10174052-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | CHRNA7, CHRNA5, CHRNA2 | KDR 2041/4885CDK5 1664/4885AURKB 3132/4885 |
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV3, TRPV2 | KDR 40/4885CDK5 1366/4885AURKB 983/4885 |
| US-20030036652-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NPY5R, NPY4R, NPY1R | KDR 628/4885CDK5 2066/4885AURKB 4791/4885 |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | KDR 68/4885CDK5 1170/4885AURKB 952/4885 |
| US-20060040964-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NPY5R, NPY4R, SSTR5 | KDR 610/4885CDK5 2094/4885AURKB 4808/4885 |
| US-20170305929-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA2 | KDR 2970/4885CDK5 1857/4885AURKB 3273/4885 |
| US-20050033048-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines | NPY5R, NPY4R, SSTR5 | KDR 610/4885CDK5 2090/4885AURKB 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.